Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Discovery of allosteric MALT1 protease inhibitor JNJ-67856633 for cancer

April 16, 2021

JNJ-74856665 mediates potent antileukemic activity and differentiation in preclinical models

April 16, 2021

Nanjing TransThera Biosciences presents TAM family kinase inhibitors

April 16, 2021

Betta Pharmaceuticals identifies EGFR inhibitors

April 16, 2021

Novartis divulges new EED and/or EZH2 inhibitors

April 16, 2021

FDA lifts partial clinical hold on phase I study of SBP-101 in pancreatic cancer

April 16, 2021

New target identified for treatment-resistant colorectal cancer

April 15, 2021

CDC7 inhibitor TQB-3824 shows promise in preclinical study

April 15, 2021

Promising results for triple A1/A2A/A2B adenosine receptor antagonist in cancer immunotherapy

April 15, 2021

Shenzhen Targetrx Biotechnology identifies mutant EGFR and HER2 inhibitors

April 15, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.